Paxillin expression was found to correlate with HER-2 gene amplification in 314 cases of invasive carcinoma, which led to speculation about whether paxillin might be a marker that could influence the predictive value of HER-2 regarding the response to adjuvant treatment.21 This evidence concerns the gene ERBB2 and invasive carcinoma.